Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia.
Autorzy:
Espirito Santo A; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal.; Faculty of Medicine, University of Porto, 4000-286 Porto, Portugal. Chacim S; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Ferreira I; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Leite L; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Moreira C; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Pereira D; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Dantas M; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Nunes M; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Viterbo L; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Moreira I; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Martins A; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Oliveira I; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Domingues N; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Mariz J; Department of Onco-Hematology, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Medeiros R; Molecular Oncology Group-CI, Portuguese Institute of Oncology, 4200-072 Porto, Portugal.; Abel Salazar Institute of Biomedical Sciences, University of Porto, 4000-286 Porto, Portugal.; Oncology Department, Portuguese Institute of Oncology, 4200-072 Porto, Portugal.; Biomedical Research Center, Faculty of Health Sciences, Fernando Pessoa University, 4000-286 Porto, Portugal.; Research Department, Portuguese League Against Cancer, 4200-072 Porto, Portugal.
Pokaż więcej
Źródło:
Molecular and clinical oncology [Mol Clin Oncol] 2017 Mar; Vol. 6 (3), pp. 384-388. Date of Electronic Publication: 2017 Jan 20.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies